Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2006

View Archived Issues

Plans for clinical investigation of low-dose cortisol for chronic PTSD

huC242-DM4 appears safe in phase I study

Assay predicts response to imatinib in CML patients

Antiarthritic potential of the novel ADAM inhibitor S-44029 demonstrated in vitro

NDA filed for Zingo needle-free local anesthetic

Milk thistle components suppress the growth of colon cancer cells

Snapshots on novel targets in autosomal dominant polycystic kidney disease

Codevelopment agreements terminated for HFT-290 and NS-126

Positive results for Atopiclair in pediatric atopic dermatitis

Inex clears another hurdle towards spin-out of Tekmira

A-831 begins phase I for hepatitis C

Mayne Pharma to acquire remaining worldwide rights to Nipent

Sanofi-aventis reflects on Q3 achievements

Promising preliminary clinical results for Aegerion's novel MTP inhibitor

Myocardial protection from postconditioning may be mediated by adenosine A2B receptors

New anticancer agents imparted in recent patents

Recent patent literature reports new therapeutic agents insomnia, anxiety, etc.

Novel PDE4 inhibitors patented by Boehringer Ingelheim, Ranbaxy

New antiarthritic compounds discovered according to recent patents

MKC-1106-PP immunotherapy cleared for phase I study in solid malignancies

Enrollment complete in phase IIa bipolar disorder trial of MEM-1003

Positive interim findings for Cethrin in treatment of acute spinal cord injury

Treatment under way in phase III study of phenoxodiol in ovarian cancer

Halozyme completes enrollment in study of Enhanze Technology

Schering AG and Stanford University collaborate on molecular imaging

Organon and Pfizer discontinue asenapine collaboration

Further positive findings for AN-152 in gynecological and breast cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.